3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Infectious Mononucleosis
1
Epstein-Barr Virus Infections
1
Interventions
pembrolizumab
2
Rituximab
2
valomaciclovir
1
threonic acid
1
otelixizumab
1
brincidofovir
1
Valganciclovir
1
Valacyclovir
1
Tenofovir
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Matrix-M
1
Magnesium Sulfate
1
Lenalidomide
1
Brentuximab Vedotin
1
Bevacizumab
1
3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Epstein-Barr Virus Infections
×
valomaciclovir
×
Clear all
NCT00575185
2017-03-22
Mono6
University of Minnesota
Phase 1/2
Completed
23 enrolled
8 charts